VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | CAR-T and allo-SCT: landscape for myeloma and DLBCL

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the current landscape of chimeric antigen receptor T-cell (CAR-T) therapy in the context of stem cell transplantation (SCT) for patients with multiple myeloma or diffuse large B-cell lymphoma (DLBCL). Prof. Kröger highlights upcoming results, comparing CAR-T and autologous-SCT in patients with DLBCL. Prof. Kröger shares that he anticipates an increase in the use of CAR-T in both advanced-stage and early-stage multiple myeloma in the near future. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter